Humacyte, Inc.
HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designedā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.17
Price-2.50%
-$0.03
1Y
Price
Market Cap
$167.097m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1730.8%
EBITDA Margin-2325.4%
Net Profit Margin-3181.0%
Free Cash Flow Margin-1730.8%
EBITDA Margin-2325.4%
Net Profit Margin-3181.0%
Free Cash Flow MarginRevenue
$8.799m
-
1y CAGR-33.3%
3y CAGR-19.0%
5y CAGREarnings
-$36.969m
+75.1%
1y CAGR-261.6%
3y CAGR-182.5%
5y CAGREPS
-$0.23
+81.8%
1y CAGR-242.6%
3y CAGR-161.5%
5y CAGRBook Value
-$4.751m
$91.509m
Assets$96.260m
Liabilities$29.825m
DebtDebt to Assets
32.6%
-1.6x
Debt to EBITDAFree Cash Flow
-$106.403m
-6.7%
1y CAGR-14.4%
3y CAGR-8.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company